Structure Therapeutics, Inc. (GPCR)
22.19
+0.31
(+1.42%)
USD |
NASDAQ |
Oct 15, 16:00
22.16
-0.03
(-0.14%)
After-Hours: 20:00
Structure Therapeutics Cash from Operations (TTM) : -220.84M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -220.84M |
| March 31, 2026 | -155.20M |
| December 31, 2025 | -222.79M |
| September 30, 2025 | -194.53M |
| June 30, 2025 | -163.35M |
| March 31, 2025 | -134.97M |
| Date | Value |
|---|---|
| December 31, 2024 | -116.69M |
| September 30, 2024 | -102.17M |
| June 30, 2024 | -103.02M |
| March 31, 2024 | -93.27M |
| December 31, 2023 | -79.42M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Eli Lilly & Co. | 28.08B |
| Novo Nordisk A/S | 20.59B |
| Pfizer Inc. | 13.40B |
| Viking Therapeutics, Inc. | -418.44M |
| Liquidia Corp. | 167.71M |